CURIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.47 USD | -0.34% |
|
+1.12% | +13.49% |
| 09/02 | HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating | MT |
| 08/02 | Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 8.35M 697M | Sales 2025 * | 8.74M 728M | Capitalization | 85.29M 7.11B |
|---|---|---|---|---|---|
| Net income 2024 * | -49M -4.09B | Net income 2025 * | -55M -4.59B | EV / Sales 2024 * | 10.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.76 x |
| P/E ratio 2024 * |
-2.39
x | P/E ratio 2025 * |
-2.66
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Curis, Inc.
More recommendations
More press releases
| 1 day | -0.34% | ||
| 1 week | +1.12% | ||
| Current month | +33.12% | ||
| 1 month | +43.41% | ||
| 3 months | +40.62% | ||
| 6 months | +257.28% | ||
| Current year | +13.49% |
1 week
14.06
15.07
1 month
10.4117.49
Current year
8.2417.49
1 year
3.8019.60
3 years
3.80348.00
5 years
3.80348.00
10 years
3.80375.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 29/16/29 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 26/22/26 |
| Chief Tech/Sci/R&D Officer | - | 03/22/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 01/03/01 | |
| Chairman | 82 | 14/00/14 | |
James Dentzer
CEO | Chief Executive Officer | 57 | 29/16/29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 14.47 | -0.34% | 10,913 |
| 25/24/25 | 14.52 | -1.69% | 10,246 |
| 24/24/24 | 14.77 | -1.60% | 4,734 |
| 23/24/23 | 15.01 | +1.08% | 5,785 |
| 22/24/22 | 14.85 | +3.77% | 21,156 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
14/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.47
USD
Average target price
93
USD
Spread / Average Target
+542.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.49% | 85.29M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CRIS Stock
